Zobrazeno 1 - 10
of 89
pro vyhledávání: '"L T, Friedhoff"'
Publikováno v:
Current Medical Research and Opinion. 20:13-18
to compare the efficacy and safety of 20 mg of lovastatin when administered once daily as an extended-release (ER) tablet or as an immediate-release (IR) tablet.Male or female patients aged 21-70 years with hypercholesterolemia who provided written i
Autor:
Sharma A; Natural Products & Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, 180001, India.; Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, 201002, India., Sharma M; Natural Products & Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, 180001, India.; Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, 201002, India., Bharate SB; Natural Products & Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu, 180001, India.; Academy of Scientific & Innovative Research (AcSIR), Ghaziabad, 201002, India.; Department of Natural Products & Medicinal Chemistry, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, 500007, India.
Publikováno v:
ChemMedChem [ChemMedChem] 2024 Oct 16; Vol. 19 (20), pp. e202400384. Date of Electronic Publication: 2024 Aug 23.
Autor:
S. L. Rogers, Hans-Jürgen Möller, Martin N. Rossor, L. T. Friedhoff, Alistair Burns, Serge Gauthier, H. Petit, Jane Hecker
Publikováno v:
Dementia and Geriatric Cognitive Disorders. 10:237-244
Donepezil has been shown to be well tolerated and to improve cognition and global function in patients with mild to moderately severe Alzheimer’s disease (AD). The current trial was undertaken to investigate further the efficacy and safety of donep
Autor:
A, Burns, M, Rossor, J, Hecker, S, Gauthier, H, Petit, H J, Möller, S L, Rogers, L T, Friedhoff
Publikováno v:
Dementia and geriatric cognitive disorders. 10(3)
Donepezil has been shown to be well tolerated and to improve cognition and global function in patients with mild to moderately severe Alzheimer's disease (AD). The current trial was undertaken to investigate further the efficacy and safety of donepez
Publikováno v:
Neurology. 52(1)
To the Editor: From their study of donepezil, Rogers et al. conclude that this drug is “efficacious in treating symptoms of memory and cognitive loss in patients with mild to moderately severe AD.”1 The following characteristics of their methodol
Publikováno v:
British journal of clinical pharmacology. 46
The aim of this study was to characterize the pharmacokinetics and pharmacodynamics of donepezil HCl, a new, chemically distinct and specific acetylcholinesterase (AChE) inhibitor for the treatment of Alzheimer's disease, following multiple-dose admi
Autor:
S L, Rogers, L T, Friedhoff
Publikováno v:
British journal of clinical pharmacology. 46
The aim of this study was to characterize the pharmacokinetic and pharmacodynamic profile of donepezil HCl, a chemically distinct and specific acetylcholinesterase (AChE) inhibitor for the treatment of Alzheimer's disease, following administration of
Publikováno v:
British journal of clinical pharmacology. 46
The aim of this study was to evaluate the pharmacokinetics of donepezil HCl (5 mg) in patients with moderately to severely impaired renal function (creatinine clearance:30 ml min(-1) 1.73 m(-2)), following the administration of single oral doses.This
Publikováno v:
British journal of clinical pharmacology. 46
The aim of this study was to examine the pharmacokinetics of donepezil HCl and ketoconazole separately, and in combination, following administration of single and multiple oral doses.This was an open-label, randomized, three-period crossover study in
Publikováno v:
British journal of clinical pharmacology. 46
The aim of this study was to evaluate the pharmacokinetic profile of donepezil HCl (5 mg) in patients with impaired hepatic function, following the administration of single oral doses.This was an open-label, non-randomized study comparing the pharmac